{
  "title": "The GLP-1 Solvency Paradox: Employer Bankruptcy vs. Long-Term Value",
  "slug": {"current": "glp1-employer-solvency-crisis"},
  "pillar": "Economics",
  "status": "Active",
  "impactLevel": "Critical",
  "summary": "Weight loss drugs are breaking the actuarial models of self-insured employers. We analyze the collision between a $12,000 annual cost and the 3-year employee churn cycle.",
  "publishedAt": "2025-12-12T08:00:00.000Z",
  "body": [
    {
      "_key": "block-1",
      "_type": "block",
      "style": "normal",
      "children": [
        {
          "_key": "span-1",
          "_type": "span",
          "text": "The clinical efficacy of GLP-1 agonists (Wegovy, Zepbound) is indisputable. The economic math, however, is currently broken for the primary payers of US healthcare: Self-Insured Employers."
        }
      ]
    },
    {
      "_key": "block-2",
      "_type": "block",
      "style": "h2",
      "children": [{"_key": "span-2", "_type": "span", "text": "1. The Wrong Pocket Problem"}]
    },
    {
      "_key": "block-3",
      "_type": "block",
      "style": "normal",
      "children": [
        {
          "_key": "span-3",
          "_type": "span",
          "text": "The core friction is temporal. The cost of a GLP-1 regimen is immediate ($1,000/month), but the ROI (reduction in cardiac events, stroke, and joint replacement) accrues over 5-10 years. In a market where the average employee tenure is only 3.2 years, employers are effectively subsidizing future savings for Medicare, not themselves."
        }
      ]
    },

    {
      "_key": "image-1",
      "_type": "image",
      "alt": "Chart showing cumulative cost of GLP-1s vs cumulative savings from avoided cardiac events over 10 years",
      "caption": "Figure 1: The 'ROI Gap' - Employers reach break-even only in Year 7 [Source: HTR Actuarial Model 2025]"
    },

    {
      "_key": "block-4",
      "_type": "block",
      "style": "blockquote",
      "children": [
        {
          "_key": "span-4",
          "_type": "span",
          "text": "Key Stat: For every $1.00 spent on GLP-1s in Year 1, a self-insured employer recovers only $0.12 in avoided medical claims."
        }
      ]
    },

    {
      "_key": "block-5",
      "_type": "block",
      "style": "h2",
      "children": [{"_key": "span-5", "_type": "span", "text": "2. Budget Impact Modeling"}]
    },
    {
      "_key": "block-6",
      "_type": "block",
      "style": "normal",
      "children": [
        {
          "_key": "span-6",
          "_type": "span",
          "text": "We modeled the impact of 20% utilization uptake on a standard 5,000-life commercial plan. The results indicate a mandatory premium hike to maintain solvency."
        }
      ]
    },

    {
      "_key": "code-1",
      "_type": "code",
      "language": "json",
      "code": "[\n  { \"Metric\": \"Annual Drug Spend (Baseline)\", \"Value\": \"$4.2M\" },\n  { \"Metric\": \"GLP-1 Cost (20% Uptake)\", \"Value\": \"+$12.0M\" },\n  { \"Metric\": \"Required Premium Hike\", \"Value\": \"+22%\" },\n  { \"Metric\": \"Stop-Loss Trigger Probability\", \"Value\": \"85%\" }\n]"
    },

    {
      "_key": "block-7",
      "_type": "block",
      "style": "h2",
      "children": [{"_key": "span-7", "_type": "span", "text": "3. Strategic Verdict"}]
    },
    {
      "_key": "block-8",
      "_type": "block",
      "style": "normal",
      "children": [
        {
          "_key": "span-8",
          "_type": "span",
          "text": "Employers must move from open access to 'Lifestyle-Gated' access. Coverage should be contingent on participation in a digital lifestyle change program, which data shows increases adherence and improves off-ramping success rates."
        }
      ]
    }
  ]
}
